RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Cash from operations

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.9B
P/E ratio
SummaryFinancials
Period EndCash from operations (Million USD)YoY (%)
Dec 31, 2024-8-107.98%
Dec 31, 2023104-119.24%
Dec 31, 2022-541-15.65%
Dec 31, 2021-642+4.35%
Dec 31, 2020-615+120.87%
Dec 31, 2019-278-50.51%
Dec 31, 2018-563+46.98%
Dec 31, 2017-383+24.40%
Dec 31, 2016-308+62.68%
Dec 31, 2015-189+14.19%
Dec 31, 2014-166+141.26%
Dec 31, 2013-69-40.61%
Dec 31, 2012-116+32.78%
Dec 31, 2011-87+3.23%
Dec 31, 2010-84

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)